Announces US FDA Approval of Speedboat RS2

RNS Number : 4701O

Creo Medical Group PLC

21 August 2017

 

Creo Medical Group plc

("Creo" or "the Company")

Announces US FDA Approval of Speedboat RS2

Approval comes ahead of schedule; Company to implement commercial plans

Chepstow, South Wales - 21 August 2017 - Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, today announces that it has received 510(k) clearance ("FDA Clearance") from the US Food and Drug Administration ("FDA") for its Speedboat RS2 device and the CROMA platform.

Speedboat RS2 is the first of a range of medical devices in development, powered by the CROMA platform, and enables the minimally invasive removal of early stage cancerous and pre-cancerous lesions in the bowel through an endoscopic procedure. This FDA Clearance has been received ahead of schedule, with the FDA review process being completed in 49 calendar days from submission. Accordingly, Creo will now assess the necessary steps to bring forward the implementation of its commercial plans for the US.

Speedboat RS2 is the first device developed for use with the Company's generator, CROMA. It harnesses the cut and coagulation capability of CROMA and enables the removal of early stage cancerous and pre-cancerous lesions. The use of Speedboat RS2 reduces the risks associated with incisions which are necessary for laparoscopic procedures and can reduce the length of hospital stay. Endoscopy has been a rapidly expanding practice due to the advent of colorectal cancer screening in most healthcare systems. This has driven growth in equipment and devices to enhance the ability to screen and detect early stage and pre-cancerous lesions in the GI tract.

In the US, over 16 million colonoscopies are performed annually. Of these, 1.1 million are likely to find a lesion requiring treatment, half of which are surgically removed. Traditional colorectal surgery is associated with a 6 per cent mortality rate at 30 days. Due to Speedboat RS2's ability to coagulate bleeding vessels when the microwave energy is activated by the surgeon, and to cut or resect when the RF energy is activated, the risk of puncturing tissue could be reduced, offering surgeons a minimally invasive alternative with an enhanced safety profile.

Craig Gulliford, Chief Executive Officer of Creo, commented: "The FDA Clearance of Speedboat RS2 and the CROMA system, earlier than planned, is a critical step in our commercialisation strategy. Speedboat is paving the way for our suite of GI devices, which we plan to commercialise in the EU, US and globally.

"This approval is a real testament to the hard work and dedication from the Creo team - we continue to execute against our plan and, in this case, come in well ahead of our targets. This bodes well and provides us with confidence that we have the foundations in place to execute on the suite of devices currently in development.

"Over the coming weeks, we will be looking to bring forward the development of our US capabilities whilst continuing with the promising training programme underway in Europe. Surgical endoscopy is an emerging field and we believe that with the CROMA system, Speedboat and our suite of products, we are well positioned to become a leader in this billion-dollar plus market."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts

Creo Medical:

Roseanne Varner

[phone]

[e-mail]

Cenkos:

Ivonne Cantu / Camilla Hume (NOMAD) 

Michael Johnson / Russell Kerr (Sales)

[phone]

FTI Consulting:

Brett Pollard / Mo Noonan / Hanna Skeppner

[phone]

[e-mail] 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

 

END

 

 

REAPPMRTMBABBBR